Silence Therapeutics (NASDAQ:SLN) Price Target Raised to $49.00 at Morgan Stanley

Silence Therapeutics (NASDAQ:SLN) had its price target lifted by Morgan Stanley from $45.00 to $49.00 in a research note released on Friday, Benzinga reports. They currently have an overweight rating on the stock.

SLN has been the topic of a number of other research reports. Chardan Capital boosted their price objective on shares of Silence Therapeutics from $42.00 to $55.00 and gave the company a buy rating in a research report on Friday. HC Wainwright reissued a buy rating and set a $75.00 target price on shares of Silence Therapeutics in a research note on Thursday.

Silence Therapeutics Stock Performance

SLN stock opened at $19.00 on Friday. Silence Therapeutics has a twelve month low of $4.84 and a twelve month high of $27.72. The firm’s fifty day simple moving average is $21.15 and its two-hundred day simple moving average is $20.95.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 16th. The company reported ($0.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.18. Silence Therapeutics had a negative net margin of 131.44% and a negative return on equity of 79.90%. The business had revenue of $15.73 million for the quarter, compared to analysts’ expectations of $4.53 million. Analysts anticipate that Silence Therapeutics will post -1.52 EPS for the current year.

Institutional Trading of Silence Therapeutics

A number of large investors have recently made changes to their positions in the stock. Redmile Group LLC purchased a new stake in shares of Silence Therapeutics during the first quarter valued at $43,798,000. Vivo Capital LLC lifted its stake in Silence Therapeutics by 116.7% in the first quarter. Vivo Capital LLC now owns 1,105,454 shares of the company’s stock worth $23,878,000 after acquiring an additional 595,250 shares during the period. Janus Henderson Group PLC purchased a new stake in Silence Therapeutics in the first quarter worth about $13,575,000. Lynx1 Capital Management LP lifted its stake in Silence Therapeutics by 123.4% in the first quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock worth $11,375,000 after acquiring an additional 290,855 shares during the period. Finally, Parkman Healthcare Partners LLC lifted its stake in Silence Therapeutics by 20.8% in the fourth quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock worth $4,046,000 after acquiring an additional 40,063 shares during the period. 98.73% of the stock is owned by hedge funds and other institutional investors.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.